David Maloney, MD, PhD

No bio available.

Financial relationships

  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Juno therapeutics
    Topic: 
    Research funding paid to my institution
    Date added: 
    04/25/2023
    Relationship end date: 
    12/31/2030
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Celgene
    Topic: 
    Research funding paid to my institution
    Date added: 
    04/25/2023
    Relationship end date: 
    12/31/2030
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Legend Biotech
    Topic: 
    Research funding paid to my institution
    Date added: 
    04/25/2023
    Relationship end date: 
    12/31/2024
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Bristol-Myers Squibb
    Topic: 
    Research funding paid to my institution
    Date added: 
    04/25/2023
    Relationship end date: 
    12/31/2030
  • Attribution: 
    Self
    Type of financial relationship: 
    Patent
    Ineligible company: 
    Juno Therapeutics/BMS
    Topic: 
    Dr. Maloney has the rights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMS
    Date added: 
    04/25/2023
    Relationship end date: 
    07/02/2024
  • Attribution: 
    Self
    Type of financial relationship: 
    Stock Options
    Ineligible company: 
    A2 Biotherapeutics
    Topic: 
    Member, Scientific Advisory Board
    Date added: 
    04/25/2023
    Relationship end date: 
    12/30/2030
  • Attribution: 
    Self
    Type of financial relationship: 
    Stock Options
    Ineligible company: 
    Navan Technologies
    Topic: 
    Member, Scientific Advisory Board
    Date added: 
    04/25/2023
    Relationship end date: 
    12/30/2030
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Chimeric Therapeutics
    Topic: 
    Member, Scientific Advisory Board
    Date added: 
    04/25/2023
    Relationship end date: 
    12/30/2030
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Genentech
    Topic: 
    Member and Chair, Lypmphopma Steering Committee
    Date added: 
    04/25/2023
    Relationship end date: 
    12/30/2030
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    BMS
    Topic: 
    Member, JCAR017 EAP-001 Safety Review Committee and the CLL Strategic Council
    Date added: 
    04/25/2023
    Relationship end date: 
    12/30/2030

Pages

Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes